Xiaoqing Guo Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

National Center for Toxicological Research

faculty

33 h-index 141 pubs 3,653 cited

Research Areas

Pharmacological Effects and Toxicity Studies Carcinogens and Genotoxicity Assessment Extracellular vesicles in disease SARS-CoV-2 and COVID-19 Research Molecular Biology Techniques and Applications Immune Response and Inflammation Liver Disease Diagnosis and Treatment Receptor Mechanisms and Signaling

Links

ORCID Google Scholar Lab Website Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Xiaoqing Guo is a faculty member at the National Center for Toxicological Research, leading a research group focused on toxicology and related biological mechanisms. Guo's work has investigated the safety and immunogenicity of SARS-CoV-2 vaccines in specific patient populations, such as those with chronic liver diseases. Additionally, Guo's research delves into the mechanisms of genotoxicity and mutagenicity, examining compounds like N-nitroso propranolol using both bacterial and human in vitro assays. This includes developing and applying advanced methods for genotoxicity testing, such as high-throughput micronucleus assays with three-dimensional cell cultures and quantitative in vitro to in vivo extrapolation models to predict protective doses.

Further research by Guo explores the role of extracellular vesicles in biological processes, particularly in the cornea, and their potential influence on cell migration. The group also investigates fundamental molecular processes, including the oligomerization and pharmacological regulation of G protein-coupled purinergic receptors. Guo's scholarship is recognized by a high citation count and an h-index of 33, reflecting a significant publication record of 141 total works.

Metrics

h-index: 33
Publications: 141
Citations: 3,653

Selected Publications

Mutation accumulation following extended exposure of human HepaRG cells to a genotoxic carcinogen (2025) DOI
NAD(P)+-dependent alcohol oxidoreductases oxidize 7-hydroxycannabidiol to a reactive formyl metabolite (2025) DOI
Background Mutation Frequencies in <scp>TK6</scp> and <scp>L5178Y</scp> Cells: Implications for Error‐Corrected Sequencing (2025) DOI
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cell models (2025) DOI
Review of black cohosh-induced toxicity and adverse clinical effects (2025) DOI
Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing (2025) DOI
Comparative DNA damage induced by eight nitrosamines in primary human and macaque hepatocytes (2025) DOI
Integration of the rat liver micronucleus assay into a 28-day treatment protocol: testing the genotoxicity of 4 small-molecule nitrosamines with different carcinogenic potencies and tumor target specificities (2025) DOI
Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells (2024) DOI
Isolation and Cryopreservation of Primary Macaque Hepatocytes (2024) DOI
Evaluating the mutagenicity of N-nitrosodimethylamine in 2D and 3D HepaRG cell cultures using error-corrected next generation sequencing (2024) DOI
Application of HepaRG cells for genotoxicity assessment: a review (2024) DOI
Key Challenges for <i>In Vitro</i> Testing of Tobacco Products for Regulatory Applications: Recommendations for the <i>In Vitro</i> Mouse Lymphoma Assay (2023) DOI
The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib (2023) DOI
Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models (2023) DOI